SCI Pharmtech Inc
TWSE:4119
SCI Pharmtech Inc
Accounts Receivables
SCI Pharmtech Inc
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Accounts Receivables
NT$289.5m
|
CAGR 3-Years
52%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
2%
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Accounts Receivables
NT$1.4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
![]() |
Formosa Laboratories Inc
TWSE:4746
|
Accounts Receivables
NT$1.2B
|
CAGR 3-Years
16%
|
CAGR 5-Years
6%
|
CAGR 10-Years
6%
|
|
![]() |
ScinoPharm Taiwan Ltd
TWSE:1789
|
Accounts Receivables
NT$633.6m
|
CAGR 3-Years
21%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
![]() |
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Accounts Receivables
NT$7.4B
|
CAGR 3-Years
32%
|
CAGR 5-Years
27%
|
CAGR 10-Years
15%
|
|
![]() |
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Accounts Receivables
NT$1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
What is SCI Pharmtech Inc's Accounts Receivables?
Accounts Receivables
289.5m
TWD
Based on the financial report for Dec 31, 2024, SCI Pharmtech Inc's Accounts Receivables amounts to 289.5m TWD.
What is SCI Pharmtech Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
2%
Over the last year, the Accounts Receivables growth was -6%. The average annual Accounts Receivables growth rates for SCI Pharmtech Inc have been 52% over the past three years , -4% over the past five years , and 2% over the past ten years .